Zobrazeno 1 - 10
of 248
pro vyhledávání: '"Gunnar, Kvalheim"'
Autor:
Gunnar Kvalheim, Kristina Lindemann, Ben Davidson, Line Bjorge, Else Marit Inderberg, Sébastien Wälchli, Emmet McCormack, Katrin Kleinmanns, David J Warren, Erik Rokkones, Martine Lode, Nicholas P Casey, Christopher Forcados, Pascal F Gelebart, Sandy Joaquina, Emmanuelle Benard, Fatemeh Kaveh, Benjamin Caulier, Christiane Helgestad Gjerde, Elvira García de Jalón, Marit Renee Myhre
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
Background Ovarian cancer (OC) is the leading cause of death from gynecologic malignancies in the Western world. Contributing factors include a high frequency of late-stage diagnosis, the development of chemoresistance, and the evasion of host immune
Externí odkaz:
https://doaj.org/article/162ad2ed429c4bd1b84eb0e5bfee44ad
Autor:
Nadia Mensali, Hakan Köksal, Sandy Joaquina, Patrik Wernhoff, Nicholas P. Casey, Paola Romecin, Carla Panisello, René Rodriguez, Lene Vimeux, Asta Juzeniene, Marit R. Myhre, Anne Fåne, Carolina Castilla Ramírez, Solrun Melkorka Maggadottir, Adil Doganay Duru, Anna-Maria Georgoudaki, Iwona Grad, Andrés Daniel Maturana, Gustav Gaudernack, Gunnar Kvalheim, Angel M. Carcaboso, Enrique de Alava, Emmanuel Donnadieu, Øyvind S. Bruland, Pablo Menendez, Else Marit Inderberg, Sébastien Wälchli
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Abstract Osteosarcoma (OS) remains a dismal malignancy in children and young adults, with poor outcome for metastatic and recurrent disease. Immunotherapies in OS are not as promising as in some other cancer types due to intra-tumor heterogeneity and
Externí odkaz:
https://doaj.org/article/aeb35d7698f54300a9d32846913690b0
Autor:
Sólrún Melkorka Maggadóttir, Gunnar Kvalheim, Patrik Wernhoff, Stein Sæbøe-Larssen, Mona-Elisabeth Revheim, Dag Josefsen, Sébastien Wälchli, Åslaug Helland, Else Marit Inderberg
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundAdoptive cellular therapy (ACT) with genetically modified T cells aims to redirect T cells against resistant cancers through introduction of a T cell receptor (TCR). The Radium-4 TCR was isolated from a responding patient in a cancer vaccin
Externí odkaz:
https://doaj.org/article/60e4d16bba4146cda688a9bb43b7ba8b
Autor:
Nadia Mensali, Pierre Dillard, Michael Hebeisen, Susanne Lorenz, Theodossis Theodossiou, Marit Renée Myhre, Anne Fåne, Gustav Gaudernack, Gunnar Kvalheim, June Helen Myklebust, Else Marit Inderberg, Sébastien Wälchli
Publikováno v:
EBioMedicine, Vol 40, Iss , Pp 106-117 (2019)
Background: Adoptive T-cell transfer of therapeutic TCR holds great promise to specifically kill cancer cells, but relies on modifying the patient's own T cells ex vivo before injection. The manufacturing of T cells in a tailor-made setting is a long
Externí odkaz:
https://doaj.org/article/baa96d23750c455aa947c1f06061880a
Autor:
Ketil A. Camilio, Meng-Yu Wang, Brynjar Mauseth, Stein Waagene, Gunnar Kvalheim, Øystein Rekdal, Baldur Sveinbjørnsson, Gunhild M. Mælandsmo
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-12 (2019)
Abstract Background Immunochemotherapy, the combined use of immunotherapy and chemotherapy, has demonstrated great promise in several cancers. LTX-315 is an oncolytic peptide with potent immunomodulatory properties designed for the local treatment of
Externí odkaz:
https://doaj.org/article/638eb6cee08a48ca8c27c37a1050bc02
Autor:
Pierre Dillard, Nicholas Casey, Sylvie Pollmann, Patrik Vernhoff, Gustav Gaudernack, Gunnar Kvalheim, Sébastien Wälchli, Else Marit Inderberg
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
T-cell receptor (TCR) redirected T cells are considered as the next generation of care for the treatment of numerous solid tumors. KRAS mutations are driver neoantigens that are expressed in over 25% of all cancers and are thus regarded as ideal targ
Externí odkaz:
https://doaj.org/article/7fa6611b77e643bf8a6aaec304d6dca2
Autor:
Gunnar Kvalheim, Frauke Schnorfeil, Christiane Geiger, Iris Bigalke, Dolores Schendel, Dag Josefsen, Yngvar Floisand, Anna Tafuri, Kai Pinkernell
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/6c94e68e3cd24965bd724d4a6aaf018d
Autor:
Felix S Lichtenegger, Frauke M Schnorfeil, Maurine Rothe, Katrin Deiser, Torben Altmann, Veit L Bücklein, Thomas Köhnke, Christian Augsberger, Nikola P Konstandin, Karsten Spiekermann, Andreas Moosmann, Stephan Boehm, Melanie Boxberg, Mirjam HM Heemskerk, Dennis Goerlich, Georg Wittmann, Beate Wagner, Wolfgang Hiddemann, Dolores J Schendel, Gunnar Kvalheim, Iris Bigalke, Marion Subklewe
Publikováno v:
Clinical & Translational Immunology, Vol 9, Iss 3, Pp n/a-n/a (2020)
Abstract Objectives Innovative post‐remission therapies are needed to eliminate residual AML cells. DC vaccination is a promising strategy to induce anti‐leukaemic immune responses. Methods We conducted a first‐in‐human phase I study using TL
Externí odkaz:
https://doaj.org/article/3a4d0c120cb84fcc870ac9dc0f5bdade
Autor:
Even Walseng, Hakan Köksal, Ibrahim M. Sektioglu, Anne Fåne, Gjertrud Skorstad, Gunnar Kvalheim, Gustav Gaudernack, Else Marit Inderberg, Sébastien Wälchli
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-10 (2017)
Abstract Effector T cells equipped with engineered antigen receptors specific for cancer targets have proven to be very efficient. Two methods have emerged: the Chimeric Antigen Receptors (CARs) and T-cell Receptor (TCR) redirection. Although very po
Externí odkaz:
https://doaj.org/article/0e8a6236e1d04796a5c036d02bcd1d20
Autor:
Xiaoran Li, Jie Lu, Quancheng Kan, Xiaoli Li, Qiong Fan, Yaqing Li, Ruixia Huang, Ana Slipicevic, Hiep Phuc Dong, Lars Eide, Junbai Wang, Hongquan Zhang, Viktor Berge, Mariusz Adam Goscinski, Gunnar Kvalheim, Jahn M. Nesland, Zhenhe Suo
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-20 (2017)
Abstract Flavopiridol (FP) is a pan-cyclin dependent kinase inhibitor, which shows strong efficacy in inducing cancer cell apoptosis. Although FP is potent against most cancer cells in vitro, unfortunately it proved less efficacious in clinical trial
Externí odkaz:
https://doaj.org/article/bc89935f75804aa4884f583426b81b31